Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 4, 2015
Pharmacy Choice - News - Pharmaceutical Development - August 4, 2015

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/4/15 - ABLYNX INITIATES PHASE II SLE STUDY WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE
Phase II study to evaluate the efficacy and safety of ALX-0061, administered subcutaneously, in patients with moderate to severe, active systemic lupus erythematosus GHENT, Belgium, 4 August 2015- Ablynx today announced that it has administered the first dose in the Phase II STEADY study to evaluate the efficacy and safety of its anti-IL-6R Nanobod
8/4/15 - Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China
By a News Reporter-Staff News Editor at China Weekly News Cardiome Pharma Corp. announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESS? to support regulatory approval in China. "We are pleased that Eddingpharm is taking the first steps necessary to gain approval of BRI
8/4/15 - Cassiopea announces that the FDA has agreed to the Special Protocol for the Winlevi phase III trial
Cassiopea announces that the FDA has agreed to the Special Protocol for the Winlevi phase III trial. Lainate, August 4, 2015; Cassiopea SpA, a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products addressed to the topical treatment of acne, androgenic...
8/4/15 - Chimerix Completes Targeted Enrollment for Brincidofovir Phase 3 AdVise Trial for Adenovirus Infection [Saudi Press Agency (Saudi Arabia)]
-Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced completion of enrollment of the targeted 200 patients in the Phase 3 AdVise trial evaluating brincidofovir for the treatment of adenovirus infection in immunocompromised patients. Through this trial, we are finding tha
8/4/15 - GNW-News: MorphoSys and G7 Therapeutics Sign Alliance to Develop Innovative Antibody Therapeutics (english)
MorphoSys and G7 Therapeutics Sign Alliance to Develop Innovative Antibody Therapeutics. MorphoSys AG/ MorphoSys and G7 Therapeutics Sign Alliance to Develop Innovative Antibody Therapeutics. MorphoSys AG and G7 Therapeutics AG announced today that they have signed an agreement to collaborate on novel antibody therapeutics targeting G...
8/4/15 - ISIS Does It Again, LXRX Shines On TELESTAR Data, ACRX Awaits EC Approval
WASHINGTON- AcelRx Pharmaceuticals Inc. expects European Commission's decision on the approval of Zalviso, proposed for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, in late September or early October. The Committee for Medicinal Products for Human Use- the European equivalent to the FDA pan
8/4/15 - MorphoSys and G7 Therapeutics Sign Alliance to Develop Innovative Antibody Therapeutics
MorphoSys AG and G7 Therapeutics AG announced today that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors and potentially other disease-related transmembrane proteins such as ion channels. Under the terms of the agreement, G7 Therapeutics will generate a set of disease-relevant...
8/4/15 - New case study shows how MHRA advised the Cell Therapy Catapult about emerging regulatory requirements
The case study showcases how MHRA's advice and guidance helped the Cell Therapy Catapult to meet the regulatory requirements facing the development of a stem cell bank for iPS and undertake clinical trials currently taking place in Japan. CEO of the Cell Therapy Catapult, Keith Thompson, said:. Our focus is on growing the cell therapy industry in t
8/4/15 - Researchers from Saiseikai Utsunomiya Hospital Discuss Findings in Mantle Cell Lymphoma (A phase II study of bendamustine plus rituximab in Japanese...
By a News Reporter-Staff News Editor at China Weekly News Current study results on Oncology have been published. According to news reporting originating from Utsunomiya, Japan, by VerticalNews correspondents, research stated, "To evaluate the efficacy and safety of a combined regimen of bendamustine and rituximab in Japanese patients with...
8/4/15 - Seattle Genetics Posts 2nd Quarter 2015 Financial Results [Professional Services Close - Up]
Seattle Genetics reported financial results for the second quarter and six months ended June 30. "With record ADCETRIS net sales in the second quarter and a broad ongoing clinical development program comprising four phase 3 trials for a range of CD30-expressing malignancies, we are enthusiastic about the potential to expand ADCETRIS to help patien
8/4/15 - Zollinger-Ellison Syndrome (Gastrinoma) Clinical Trials Review, H1, 2015
Dublin- Research and Markets has announced the addition of the "Zollinger-Ellison Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. -Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each- Clini
8/3/15 - /OFF HOLD OFF HOLD OFF HOLD FN Media Group LLC/
/OFF HOLD OFF HOLD OFF HOLD FN Media Group LLC, PIV757417 The following release: "Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products& Treatments for Critical-Care Patients With Severe Wound Conditions" is now OFF HOLD. Biotech companies with recent developments, partnerships and advancements in f
8/3/15 - 3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015
3- V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush PacGrow Healthcare Conference in New York, NY. Merdad Parsey, Chief Executive Officer, is scheduled to present on Wednesday, August 12th at 1:55p.m. ET.
8/3/15 - Access to Kitabis Pak Expands for Patients with Cystic Fibrosis
By a News Reporter-Staff News Editor at Clinical Trials Week There is positive news for patients with cystic fibrosis using nebulized antibiotic therapy as access to Kitabis Pak has expanded in many US states. Kitabis Pak is now on the Preferred Drug List for many state programs, increasing access to the only FDA approved co-packaging of tobramyc
8/3/15 - Achillion Announces Janssen Initiated Phase I Study to Evaluate Effect of Simeprevir and Odalasvir on AL-335 Pharmacokinetics
Achillion Pharmaceuticals, Inc. announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an open-label, two-group study of simeprevir and...
8/3/15 - Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335 Pharmacokinetics
Achillion Pharmaceuticals, Inc. announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers.. As previously announced on May 19, 2015, Achillion has granted Janssen
8/3/15 - Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335... [Daily Tribune (Bahrain)]
-Achillion Pharmaceuticals, Inc. announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers. As previously announced on May 19, 2015, Achillion has granted Janssen a
8/3/15 - Acorda Awarded Grant to Study ARCUS Technology in Respiratory Distress Syndrome
By a News Reporter-Staff News Editor at Clinical Trials Week Acorda Therapeutics, Inc. announced that the Bill& Melinda Gates Foundation has awarded the Company a $1.4 million grant to support the development of a formulation and delivery system for a dry powder version of lung surfactant, a drug used to treat neonatal respiratory distress syndro
8/3/15 - Alnylam Initiates Phase 3 Open Label Extension Study "APOLLO-OLE" with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin TTR for...
Alnylam Initiates Phase 3 Open Label Extension Study "APOLLO-OLE" with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin TTR for the Treatment of TTR-Mediated Amyloidosis ATTR Amyloidosis. By a News Reporter-Staff News Editor at Clinical Trials Week Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced
8/3/15 - Amgen Submits Supplemental New Drug Application For Kyprolis Carfilzomib In Relapsed Multiple Myeloma
By a News Reporter-Staff News Editor at Pharma Business Week Amgen announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Kyprolis for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one p
8/3/15 - Amneal Adds Four New Products to Its Growing Portfolio
By a News Reporter-Staff News Editor at Pharma Business Week Amneal Pharmaceuticals has launched four new products since June 2015. On July 13, the company obtained FDA approval for its tobramycin inhalation solution; it is the first inhalation solution formulation offered by Amneal. For some time, patients and payers have been eagerly awaiting..
8/3/15 - Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015
Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. Ron Squarer, Chief Executive Officer of Array, noted, "Binimetinib and encorafenib, two innovative oncology products in Phase 3, are on track for regulatory submissions in 2016. Additional data shared over the summer in BRAF-mu
8/3/15 - Austin Pain Associates Seeks Patients With Complex Regional Pain Syndrome for Clinical Trial of Infusion Therapy Using Neridronic Acid
Austin Pain Associates, the leader in pain management in central Texas, is pleased to announce that it is participating in a clinical trial to study the efficacy of infusion therapy using neridronic acid to treat Type I complex regional pain syndrome. Neridronic acid was developed from a class of drugs historically used to treat osteoporosis and is
8/3/15 - Bayer's Finacea gets FDA approval to treat Papulopustular rosacea [Seven Days (United Arab Emirates)]
Bayer HealthCare has received approval from the US Food and Drug Administration for Finacea Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The FDA approval is based on results from two pivotal clinical trials evaluating the efficacy and safety of Finacea Foam compared to the foam vehicle in
8/3/15 - BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-283 for Solid Tumor Cancers
"We are delighted to receive CTA approval in China from the CFDA to start BGB-283 clinical trials in China," said John V. Oyler, CEO of BeiGene. "Gaining trial approval in China is historically a lengthy, stringent process with high pharmaceutical standards that must be met to start human clinical trials. The clinical trials in China will investig
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415